Scottish_JJ breast_NN1 cancer_NN1 drug_NN1 discovery_NN1 offers_VVZ new_JJ treatment_NN1 hope_NN1 
Scientists_NN2 have_VH0 identified_VVN a_AT1 chemical_JJ compound_NN1 that_DD1 is_VBZ highly_RR effective_JJ at_II blocking_VVG the_AT growth_NN1 of_IO breast_NN1 cancer_NN1 cells_NN2 in_II the_AT laboratory_NN1 ._. 
A_AT1 new_JJ breast_NN1 cancer_NN1 treatment_NN1 which_DDQ destroys_VVZ tumours_NN2 more_RGR effectively_RR than_CSN existing_JJ medicines_NN2 could_VM be_VBI on_II the_AT horizon_NN1 ,_, according_II21 to_II22 a_AT1 "_" promising_JJ "_" study_NN1 ._. 
Edinburgh_NP1 University_NP1 scientists_NN2 have_VH0 pinpointed_VVN a_AT1 chemical_JJ compound_NN1 called_VVN eCF506_FO that_DD1 is_VBZ highly_RR effective_JJ at_II blocking_VVG the_AT growth_NN1 of_IO breast_NN1 cancer_NN1 cells_NN2 in_II the_AT laboratory_NN1 ._. 
The_AT compound_NN1 targets_VVZ a_AT1 molecule_NN1 called_VVN Src_NP1 tyrosine_NP1 kinase_NP1 ,_, which_DDQ is_VBZ vital_JJ for_IF the_AT growth_NN1 and_CC spread_NN1 of_IO breast_NN1 cancer_NN1 cells_NN2 ._. 
Drugs_NN2 that_DD1 target_VV0 the_AT same_DA molecule_NN1 are_VBR already_RR being_VBG tested_VVN in_II clinical_JJ trials_NN2 but_CCB researchers_NN2 claim_VV0 this_DD1 compound_NN1 could_VM be_VBI more_RGR effective_JJ and_CC produce_VVI fewer_DAR side_NN1 effects_NN2 as_CSA it_PPH1 is_VBZ more_RGR selective_JJ in_II the_AT molecules_NN2 it_PPH1 targets_VVZ ._. 
Dr_NNB Asier_NP1 Unciti-Broceta_NP1 ,_, who_PNQS led_VVD the_AT study_NN1 at_II the_AT Cancer_NP1 Research_NP1 UK_NP1 Edinburgh_NP1 Centre_NP1 ,_, said_VVD :_: "_" eCF506_FO is_VBZ the_AT first_MD drug_NN1 candidate_NN1 of_IO a_AT1 second_MD generation_NN1 of_IO Src_NP1 inhibitors_NN2 that_DD1 will_VM not_XX only_RR help_VVI to_TO understand_VVI the_AT complexity_NN1 of_IO some_DD cancers_NN2 but_CCB also_RR the_AT development_NN1 of_IO safer_JJR combination_NN1 therapies_NN2 ._. "_" 
More_DAR than_CSN 1,000_MC people_NN die_VV0 from_II breast_NN1 cancer_NN1 in_II Scotland_NP1 every_AT1 year_NNT1 ._. 
The_AT team_NN1 used_VVD a_AT1 pioneering_JJ approach_NN1 for_IF the_AT study_NN1 where_CS they_PPHS2 tested_VVD the_AT candidate_NN1 drug_NN1 on_II human_JJ breast_NN1 cancer_NN1 cells_NN2 ,_, rather_II21 than_II22 lab-created_JJ proteins_NN2 ,_, which_DDQ allowed_VVD them_PPHO2 to_TO visualise_VVI the_AT effects_NN2 of_IO the_AT drugs_NN2 more_RGR efficiently_RR ._. 
It_PPH1 is_VBZ hoped_VVN this_DD1 technique_NN1 could_VM provide_VVI a_AT1 quicker_JJR and_CC cheaper_JJR way_NN1 of_IO discovering_VVG new_JJ medicines_NN2 ._. 
Professor_NNB Neil_NP1 Carragher_NP1 ,_, head_NN1 of_IO the_AT Edinburgh_NP1 Cancer_NP1 Discovery_NP1 Unit_NP1 ,_, who_PNQS co-led_VVD the_AT study_NN1 published_VVN in_II the_AT Journal_NP1 of_IO Medicinal_JJ Chemistry_NP1 ,_, said_VVD :_: "_" This_DD1 candidate_NN1 drug_NN1 will_VM need_VVI to_TO undergo_VVI further_RRR preclinical_JJ testing_NN1 before_CS it_PPH1 can_VM be_VBI taken_VVN forward_RL into_II clinical_JJ trials_NN2 but_CCB these_DD2 early_JJ findings_NN2 are_VBR very_RG promising_JJ ._. 
"_" This_DD1 approach_NN1 is_VBZ also_RR very_RG exciting_JJ as_II the_AT cancers_NN2 are_VBR telling_VVG us_PPIO2 how_RRQ to_TO design_VVI the_AT drugs_NN2 ._. "_" 
Mary_NP1 Allison_NP1 ,_, Scotland_NP1 Director_NP1 of_IO Breast_NP1 Cancer_NP1 Now_RT ,_, said_VVD :_: "_" Targeting_VVG some_DD proteins_NN2 involved_JJ in_II cancer_NN1 with_IW drugs_NN2 has_VHZ traditionally_RR been_VBN a_AT1 challenge_NN1 ,_, as_CSA these_DD2 drugs_NN2 might_VM also_RR have_VHI unintended_JJ consequences_NN2 on_II normal_JJ cells_NN2 as_II31 well_II32 as_II33 cancer_NN1 cells_NN2 ._. 
"_" New_JJ methods_NN2 of_IO drug_NN1 design_NN1 like_II this_DD1 research_NN1 might_VM help_VVI overcome_VVI some_DD of_IO these_DD2 hurdles_NN2 ,_, so_CS these_DD2 early_JJ findings_NN2 are_VBR a_AT1 positive_JJ step_NN1 forward_RL ._. "_" 
